You can buy or sell MNPR and other stocks, options, ETFs, and crypto commission-free!
Monopar Therapeutics Inc. Common Stock, also called Monopar Therapeutics, is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Read More Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL. The listed name for MNPR is Monopar Therapeutics Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, After Hours